Cagr 2.5mg+Sema 2.5mgCS5

Images are illustrative. Actual specifications are as selected and confirmed in writing.

GLP-1 & Metabolic Research

Cagr 2.5mg+Sema 2.5mg

Combination for weight reduction and weight management research

Cagr 2.5mg+Sema 2.5mg specifications and reference prices. Select a specification to add it to your cart.

5mg/vial x 10vials

Reference priceUS$169.70

For laboratory research only. Not for human or veterinary use.

COA 检测报告 / Reports

Compare all specifications & reference prices
SKUSpecification / packReference price (USD)
CS55mg/vial x 10vialsUS$169.70

Temporarily sold-out specifications can still be added to an inquiry to ask about restocking. An inquiry is not an order or an agreed price.

RESEARCH FOCUS

Main Uses & FAQs

This page organizes directly related data on weight loss and weight management combinations of Cagr 2.5mg+Sema 2.5mg. First, look at the research questions and findings, then check the population or species, study formulations, and scope of interpretation.

Main TopicsWeight Loss · Weight Management Combination
USAGE REFERENCE

Cagrilintide + Semaglutide (2.5+2.5) · Usage reference (for research use)

The following presents common research-context references for reconstitution, storage, dosage and cycles. The following presents common references in research settings. This page does not constitute advice for use in humans or animals.

🧪Reconstitution

Suggested Diluent
Bacteriostatic Water (containing 0.9% benzyl alcohol); some peptides may use sterile water or acetic acid to aid dissolution. See the individual product descriptions.
Diluent Volume
Slowly introduce the diluent along the vial wall until the lyophilized powder is covered. A common example is 5 mg reconstituted with 2 mL of bacteriostatic water, yielding approximately 2.5 mg/mL. Referenced reconstitution volumes are approximately 1–2.5 mL, with 2 mL commonly used. It is suggested to select and record a fixed volume based on the COA supplied with the purchase.
Handling Notes
Introduce the diluent slowly along the vial wall rather than directly onto the lyophilized powder. Leave it for 60–90 seconds to dissolve naturally; do not shake vigorously.

💾Storage

Unreconstituted Lyophilized Powder
Refrigerate at 2–8°C, protected from light; avoid repeated freeze–thaw cycles.
After Reconstitution
Refrigerate at 2–8°C; a common recommendation is touse within 28 days; do not freeze.
Transport
For short periods, use insulated packaging with ice packs; avoid high temperatures and direct light.

📏Dosage Reference (Research)

Purpose / SettingCommon Reference
Administration RouteSubcutaneous injection

🔁Cycle

Subcutaneous injection once per week.

View the Complete Usage Guide Library →

Note: The above describes common research-context references, rather than clinical recommendations. Refer to the batch COA and research protocol. For research use only; not for human or animal use.

Research SummaryKey Findings

Cagr 2.5mg+Sema 2.5mg: What research findings exist regarding weight loss and weight management combinations?

At week 68, CagriSema had an average weight loss of 18.4%, semaglutide group 11.9%. Another study reports: CagriSema group average weight loss 20.4%, placebo 3.0%, directly supporting the weight loss effect of combination study drug.[1] ↗ [2] ↗

Before ReadingStudy populations, species, formulations and delivery conditions each have a defined scope. Research on an ingredient does not establish that this site's product batches have been validated for efficacy in humans or veterinary use.
3 main theme articles · Identity/formulation needs verificationSorted by First Publication Date ↓
Human Study2026REF. 01

How does the combination therapy in Japan and Taiwan compare directly with monotherapy?

Research Findings

At week 68, CagriSema had an average weight loss of 18.4%, semaglutide group 11.9%.[1] ↗

Study Design

Human Phase III randomized; Japan/Taiwan REDEFINE-5

Scope & Limitations

Specific combinations, formulations, and inclusion criteria; three packaging specifications share literature, not three separate studies.

View the Article Title and Full Citation+

Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.

Yamauchi T, Becker NP, Hagemann CA, Huang KC, Kiyosue A, Lim S, Onishi Y, Kosuvaripalli A, Takano T, Ishigaki Y, REDEFINE 5 study group

The Lancet. Diabetes & Endocrinology · Volume and issue year 2026
First published 2026-04-17 · PMID 42009015
DOI 10.1016/S2213-8587(25)00402-4

Human Study2025REF. 02

What are the findings of the CagriSema weight loss trial in non-diabetic populations?

Research Findings

The CagriSema group had an average weight loss of 20.4%, placebo 3.0%, directly supporting the weight loss effect of the combined study formulation.[2] ↗

Study Design

REDEFINE1; 3,417 non-diabetic overweight or obese adults; 68-week randomized controlled trial

Scope & Limitations

Includes lifestyle interventions; specific combined ratios are not equivalent to study formulations in the listed product; gastrointestinal adverse events were relatively common.

View the Article Title and Full Citation+

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.

Garvey WT, Blüher M, Osorto Contreras CK, Davies MJ, Winning Lehmann E, Pietiläinen KH, Rubino D, Sbraccia P, Wadden T, Zeuthen N, Wilding JPH, REDEFINE 1 Study Group

The New England Journal of Medicine · Volume, Issue, Year 2025
First published 2025-06-22 · PMID 40544433
DOI 10.1056/NEJMoa2502081

Human Study2025REF. 03

What are the CagriSema weight results in populations with diabetes?

Research Findings

The CagriSema group had an average weight loss of 13.7%, placebo 3.4%, with weight as the primary endpoint.[3] ↗

Study Design

REDEFINE2; 1,206 overweight or obese adults with type 2 diabetes; 68 weeks

Scope & Limitations

Limited to populations with combined diabetes and study combination formulations; does not prove equivalence of different ratios or commercial batches.

View the Article Title and Full Citation+

Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.

Davies MJ, Bajaj HS, Broholm C, Eliasen A, Garvey WT, le Roux CW, Lingvay I, Lyndgaard CB, Rosenstock J, Pedersen SD, REDEFINE 2 Study Group

The New England Journal of Medicine · Volume, Issue, Year 2025
First published 2025-06-22 · PMID 40544432
DOI 10.1056/NEJMoa2502082

i

Currently, 3 original studies related to the theme of this page have been selected. The number of studies includes different designs, populations, or preparations, not commercial clinical efficacy ratings. This page is a usage-oriented positive data selection, not a systematic review or dosing recommendation. Historical studies, combination preparations, and special models are all separately indicated.

GO DEEPER

What Questions Do These Studies Address?

Compare study populations, findings and scope.

↗
QUESTIONS, ANSWERED

Cagr 2.5mg+Sema 2.5mg · Frequently Asked Questions.

Cagr 2.5mg+Sema 2.5mg: What research findings exist regarding weight loss and weight management combinations?+

At week 68, CagriSema had an average weight loss of 18.4%, semaglutide group 11.9%. Another study reports: CagriSema group average weight loss 20.4%, placebo 3.0%, directly supporting the weight loss effect of combination study drug.[1] ↗ [2] ↗

Does a 2.5mg packaging amount correspond to the dose used in the CagriSema trial?+

Not equal. Trials have specific formulations, dose escalation schemes, and populations; bottled content cannot be taken as a single clinical dose, nor does it prove that catalog mixtures are equivalent to trial formulations.[2] ↗ [3] ↗ [1] ↗

Cagr 2.5mg+Sema 2.5mg—these conclusions apply to which study populations?+

Human Phase III randomized; Japan/Taiwan REDEFINE-5; REDEFINE1; 3,417 non-diabetic overweight or obese adults; 68-week randomized controlled; REDEFINE2; 1,206 overweight or obese adults with type 2 diabetes; 68 weeks. Specific combinations, formulations, and inclusion criteria; three packaging specifications share literature, not three separate studies.[1] ↗ [2] ↗ [3] ↗

VENTRO PEPTIDES & BIOTECH · RESEARCH PRODUCT RETAIL

Research peptides. Shop by product.

Compare specifications, reference prices and COA reports. Add products to your cart to request a quote.

Ventro Peptides & Biotech Logo
QUALITY DOCUMENTSCOA BY PRODUCTGLOBAL DELIVERYTECHNICAL SUPPORT

01 / CATALOG

Browse products

7 products Product names, specifications, and prices follow the current quotation
SemaglutideSM10COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

GLP-1 & Metabolic Research

Semaglutide

10mg/vial x 10vials

US$90.91
TirzepatideTR20COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

GLP-1 & Metabolic Research

Tirzepatide

20mg/vial x 10vials

US$160.61
RetatrutideRT10COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

GLP-1 & Metabolic Research

Retatrutide

10mg/vial x 10vials

US$109.09
BPC157BC10COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

Repair & Recovery Research

BPC157

10mg/vial x 10vials

US$133.33
MOTS-CMS20COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

Longevity & Mitochondrial Research

MOTS-C

20mg/vial x 10vials

US$257.58
LiraglutideLR10COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

GLP-1 & Metabolic Research

Liraglutide

10mg*10vials

US$164.71
IGF-lr3IG1COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

Growth Hormone & IGF-1

IGF-lr3

1mg/vial x 10vials

US$505.88

03 / ABOUT VENTRO

Reliable peptide supply, built for long-term partnerships.

Ventro supports research product retail purchases with clear pack specifications, available quality documents, and responsive international support.

  • High-purity peptides
  • Available COA reports
  • COA & quality documentation
  • Flexible small-quantity purchases
  • Reliable global fulfillment
  • Research product retail support

04 / QUALITY SYSTEM

Quality without compromise

Browse the available COA reports by product. Confirm documentation for your order with our team.

Controlled quality workflowRaw material to final release
Responsive global supportProduct matching and technical support

RESEARCH PRODUCT INQUIRY

Submit a product inquiry

Tell us the product, specification, and expected quantity. Our team will respond with pricing and available documents.

Use another email app

Opening an inquiry creates a draft, not a sent message. Review and press Send in Gmail, WhatsApp or your email app. Opening a channel passes the draft to the chosen provider. Privacy & cookies

Contact Ventro

Choose a channel to contact the Ventro team directly.

Use another email app

Opening an inquiry creates a draft, not a sent message. Review and press Send in Gmail, WhatsApp or your email app. Opening a channel passes the draft to the chosen provider. Privacy & cookies

WhatsApp